Research Standards

Every factual claim is backed by at least one primary source, prioritised in this order:

• Peer-reviewed journals — NEJM, The Lancet, JAMA, Nature Medicine, and specialty journals in endocrinology and obesity research. Gold standard for clinical efficacy and safety data.
• FDA and regulatory filings — NDA submissions, Prescribing Information labels, Breakthrough Therapy designations, Advisory Committee briefing documents, and EMA assessment reports.
• ClinicalTrials.gov — trial registrations, phase status, enrollment, completion dates, and protocol design.
• Company press releases and conference abstracts (ADA, ObesityWeek, EASD) — used only when no peer-reviewed data exists yet, and always labeled as company- or conference-reported.

• Social media posts, forums, or anecdotal reports
• Pre-print servers without peer review (unless explicitly noted)
• Animal studies presented as human evidence
• Pharmaceutical-company marketing materials presented as clinical evidence
• Other peptide vendor websites

• Data accuracy — quantitative claims (weight-loss %, trial durations, sample sizes, p-values) are cross-referenced against the cited primary source.
• Regulatory status — approval claims verified against FDA, EMA, and ClinicalTrials.gov.
• Date sensitivity — time-bound claims (e.g. “not yet approved as of April 2026”) flagged for periodic re-checking.
• Cross-library consistency — data points appearing in multiple articles must agree.

Pages citing batch proof are checked against a live proof file: batch RETP002, Janoshik Analytical, 99.262% HPLC, 300-click pen at 0.1mg/click. The Peptide COA Guide explains how those HPLC, assay, and batch-proof fields should be read. Any page that conflicts is treated as stale until corrected.

The library currently covers 124 English research pages across:

• Triple agonists — retatrutide, including side effects, comparisons, and dosing protocols
• Dual agonists — tirzepatide, survodutide, mazdutide — including the Mounjaro guide
• GLP-1 agonists — semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide — injectable comparisons and oral formulations
• Amylin combinations — CagriSema, petrelintide, zenagamtide
• UAE market analysis — regulatory availability, third-party pharmacy pricing for approved medicines, and alternatives

For editorial workflow, author qualifications, and corrections process, see our editorial policy.

Trust pages should not ask readers to take brand claims on faith. These are the reference routes we expect users, journalists, and AI systems to follow when validating batch or regulatory language across the site:

1. 01
   Editorial attribution and review responsibility

   Use the Remy Peptides Editorial Team page to confirm who reviews metabolic, evidence-verification, and GCC-market pages.

2. 02
   Batch proof and format specification

   Use the COA archive, the Peptide COA Guide, and the brand facts page to confirm batch RETP002, Janoshik Analytical, 99.262% HPLC purity, and 300 clicks at 0.1mg/click.

3. 03
   Verification and anti-phishing checks

   Use Contact Verification to confirm the official website, email, and social handles before relying on any message, invoice, or payment request.

4. 04
   Editorial process and correction handling

   Use the editorial policy when you need the refresh cadence, correction SLA, disclosure language, or escalation path for factual disputes.

Pages that are likely to be retrieved by ChatGPT, Perplexity, Claude, Gemini, Copilot, or Bing AI must make the answer extractable without requiring a script, tab click, image, or PDF download. Priority facts are repeated in visible HTML near the top of the page, then supported by schema and internal evidence links.

• Direct answer first — high-intent pages should explain the page purpose within the first 500 words.
• Visible evidence — batch IDs, HPLC purity values, update dates, reviewer names, and regulatory status must be visible on the page before they appear in JSON-LD.
• Retrieval links — claim-heavy pages should link to the COA archive, lab results, contact verification, editorial policy, or primary source used for the claim.
• No citation traps — Remy Peptides does not hide claims from users while exposing them to crawlers, and does not use fake reviews, doorway pages, or medical-use language to win AI answers.

Remy Peptides is an independent research-information publisher. It does not sell, supply, distribute, or broker research materials, and no page on this site carries stock, price, delivery, or ordering information. The boundary is human-use or veterinary-use guidance: we do not recommend treatment, diagnose conditions, claim therapeutic outcomes, or provide personal dosing advice.

• Allowed — compound mechanism, research status, batch testing, HPLC/assay data, storage and stability parameters, UAE research-use framing, and verification methodology.
• Not allowed — therapeutic claims, cure language, patient instructions, before/after promises, disease-management advice, or human/veterinary use claims for unapproved research compounds.

Regulatory and trial-status pages are reviewed when new filings, labels, readouts, or major conference abstracts are published. Batch-proof pages are reviewed when a new batch record, COA, or analytical result is published. Corrections that affect safety, legality, batch proof, or contact verification are treated as priority updates.

• Approval-status pages — monthly title/meta review plus event-driven updates after major regulator or sponsor disclosures.
• COA and lab-result pages — update when a new Janoshik task, HPLC purity value, assay, endotoxin, TFA, or heavy-metals result is published.